Bangalore/Hyderabad, India , January 6, 2026: Pandorum Technologies has entered into a strategic collaboration with Hyderabad-based Nucelion Therapeutics, backed by Bharat Biotech to expand manufacturing capacity for its exosome-based therapeutic platform across the Asia-Pacific region.
Pandorum, a clinical-stage regenerative medicine company, is advancing a platform focused on programmable tissue regeneration. The partnership with Nucelion aims to support the company’s progress toward clinical trials by strengthening regional supply chains and ensuring regulatory preparedness. The move also reflects India’s growing role in developing and producing advanced biologic therapies.
Nucelion-Pandorum Pact Lays Groundwork for Biologics Production in India
Dr. Tuhin Bhowmick, Co-Founder and CEO of Pandorum Technologies, said the company is building a global regenerative medicine platform designed for scale and collaboration. He noted that as Pandorum’s programs move closer to clinical and commercial stages, establishing regionally aligned manufacturing infrastructure has become a priority. According to him, Nucelion’s experience in biologics manufacturing aligns with Pandorum’s long-term plans for delivering programmable exosome therapies.
Dr. Raghu Malapaka, CBO of Nucelion Therapeutics, said the partnership will support the development of Kuragenx, an exosome-based therapy aimed at ocular diseases. He added that Nucelion’s manufacturing systems are built to handle complex biologics and will help enable scalable production of Pandorum’s exosome assets for the APAC region.
Dr. Jitendra Kumar, Managing Director of BIRAC under the Department of Biotechnology, Government of India, said the collaboration signals the readiness of India’s innovation and manufacturing ecosystem to address global clinical needs.
Pandorum’s current programs focus on ocular surface injury and inflammatory corneal diseases, including Stevens–Johnson syndrome and Neurotrophic Keratitis. The company also plans to expand into treatments targeting degenerative changes in skin, lung, and other organs affected by inflammation, vascular disorders, and fibrosis.
Nucelion Therapeutics, a subsidiary of Bharat Biotech, will provide process scale-up, GMP-compliant production, and quality control for pharmaceutical-grade exosomes derived from clinical-grade mesenchymal stem cells.
Pandorum’s platform is built on a tunable exosome technology designed to modulate intercellular communication and support tissue repair. The company’s development framework emphasizes consistent manufacturing and data-driven clinical translation across multiple therapeutic areas.
